Test of lidocaine infusion for severe migraine or face pain
Part of Brain & nervous system clinical trials.
This trial tests whether giving a numbing medicine (lidocaine) into a small artery in the face (the external carotid artery) can help people with hard-to-treat chronic migraines or persistent face/skull pain. It is for those who haven't found relief from standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have chronic migraine, a severe migraine that won't stop, or face/skull pain that hasn't improved with standard treatments.
- You must be able to understand the trial and give written permission (informed consent) to take part.
- You cannot be allergic to lidocaine (a type of numbing medication).
- You cannot have a history of seizures or a seizure disorder.
- You cannot have a pacemaker, cochlear implant, or other implanted electronic device.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a lidocaine infusion into an artery in the head can reduce severe chronic daily headaches. It is for people who have tried multiple treatments without enough relief.
This trial tests a minimally invasive procedure that blocks a blood vessel in the brain to reduce migraine attacks. It may help people who have frequent migraines and haven't found relief with standard migraine medications.
This study tests a numbing medicine placed in the nose to relieve migraine pain and sinus pressure. It can help people who have frequent headaches with sensitivity to light, nausea, or trouble functioning.
This study follows adults who undergo a procedure called middle meningeal artery embolization—a minimally invasive treatment that blocks blood flow to a specific artery thought to trigger migraines. The trial simply tracks your symptoms and quality of life before and after the procedure to understand how well it works.
This trial tests a substance that activates adrenomedullin receptors, which may be a new way to treat migraines. It may help people who have migraines without aura and aren't on preventive migraine medications.
This study tests a new inhaled powder form of a migraine medication called dihydroergotamine (DHE) to see if it safely and effectively stops migraine attacks. If you have frequent migraines, this trial might offer you a new treatment option to try.
Hear when a new Migraine trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.